Efflux pumps of gram-negative bacteria, a new target for new molecules

Current Topics in Medicinal Chemistry

Volumn 10, Issue 18, 2010, Pages 1848-1857

  Pagès, Jean Marie ^a,b   Alibert Franco, Sandrine ^a,b   Mahamoud, Abdallah ^a   Bolla, Jean Michel ^a   Davin Regli, Anne ^a,b   Chevalier, Jacqueline ^a   Garnotel, Eric ^a  

^a Aix Marseille University   (France)

^b COST Action BM0701 ^*  (France)

Author keywords

AcrAB TolC structure and function; Bacterial resistance modulators; Efflux pump and drug transporters; Efflux pump inhibitors and blockers; Multi drug resistance (MDR)

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAM; CHLORAMPHENICOL; CYMBOPOGON CITRATUS EXTRACT; EFFLUX PUMP INHIBITOR; ERYTHROMYCIN; EUGENIA AROMATICA EXTRACT; GENTAMICIN; HELICHRYSUM ITALICUM EXTRACT; HUMULUS LUPULUS EXTRACT; KANAMYCIN; MENTHA AVENSIS EXTRACT; NORFLOXACIN; PEPTIDOMIMETIC AGENT; PHENOTHIAZINE DERIVATIVE; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; PLANT EXTRACT; POLYMYXIN B; QUINOLINE DERIVATIVE; RIFAMPICIN; STREPTOMYCIN; TETRACYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ACTIVE TRANSPORT; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM ISOLATE; DRUG BINDING SITE; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; GENE EXPRESSION; GRAM NEGATIVE BACTERIUM; MEMBRANE TRANSPORT; MULTIDRUG RESISTANCE; NONHUMAN; PSEUDOMONAS AERUGINOSA;

EID: 78649912244     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802610793176620     Document Type: Article

References (112)

1. Rice, L. B. Unmet medical needs in antibacterial therapy. Biochem. Pharmacol., 2006, 71, 991-995.
2. Falagas, M. E.; Bliziotis, I. A. Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era? Int. J. Antimicrob. Agents, 2007, 29, 630-636.
3. Chopra, I.; Schofield, C.; Everett, M.; O'Neill, A.; Miller, K.; Wilcox, M.; Frère, J. M.; Dawson, J. M.; Czaplewski, L.; Urleb, U.; Courvalin, P. Treatment of health-care-associated infections caused by Gram-negative bacteria: a consensus statemen. Lancet Infect. Dis., 2008, 8, 133-139.
4. Blot, S.; Depuydt, P.; Vandewoude, K.; De Bacquer, D. Measuring the impact of multidrug resistance in nosocomial infection. Curr. Opin. Infect. Dis., 2007, 20, 391-396.
5. Alekshun, M. N.; Levy, S. B. Molecular mechanisms of antibacterial multidrug resistance. Cell, 2007, 128, 1037-1050.
6. Nikaido, H. Multidrug resistance in bacteria. Annu. Rev. Biochem., 2009, 78, 119-146.
7. Piddock, L. J. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin. Microbiol. Rev., 2006, 19, 382-402.
8. Davin-Regli, A.; Bolla, J. M.; James, C. E.; Lavigne, J.P.; Chevalier, J.; Garnotel, E.; Molitor, A.; Pagès, J. M. Membrane permeability and regulation of drug influx and efflux in enterobacterial pathogens. Curr. Drug Targets, 2008, 9, 750-759.
9. Pagès, J.-M.; James, C. E.; Winterhalter, M. The porin and the permeating antibiotic: a selective diffusion barrier in Gramnegative bacteria. Nat. Rev. Microbiol., 2008, 6, 893-903.
10. Martinez, J. L.; Sánchez, M. B.; Martínez-Solano, L.; Hernandez, A.; Garmendia, L.; Fajardo, A.; Alvarez-Ortega, C. Functional role of bacterial multidrug efflux pumps in microbial natural ecosystems. FEMS Microbiol. Rev., 2009, 33, 430-449.
11. Li, X. Z.; Nikaido, H. Efflux-mediated drug resistance in bacteria. Drugs, 2004, 64, 159-204.
12. Poole, K. Efflux-mediated antimicrobial resistance. J. Antimicrob. Chemother., 2005, 56, 20-51.
13. Poole, K. Efflux pumps as antimicrobial resistance mechanisms. Ann. Med., 2007, 39, 162-176.
14. Piddock, L. J. Multidrug-resistance efflux pumps - not just for resistance. Nat. Rev. Microbiol., 2007, 4, 629-636.
15. Ricci, V.; Tzakas, P.; Buckley, A.; Piddock, L. J. Ciprofloxacinresistant Salmonella enterica serovar Typhimurium strains are difficult to select in the absence of AcrB and TolC. Antimicrob. Agents Chemother., 2006, 50, 38-42.
16. Yan, M.; Sahin, O.; Lin J.; Zhang, Q; Role of the CmeABC efflux pump in the emergence of fluoroquinolone-resistant Campylobacter under selection pressure. J. Antimicrob. Chemother., 2006, 58, 1154-1159.
17. Quinn, T.; O'Mahony, R.; Baird, A. W.; Drudy, D.; Whyte, P.; Fanning, S. Multi-drug resistance in Salmonella enterica: efflux mechanisms and their relationships with the development of chromosomal resistance gene clusters. Curr. Drug Targets, 2006, 7, 849-860.
18. Chevalier, J.; Mulfinger, C.; Garnotel, E.; Nicolas, P.; Davin-Régli, A.; Pagès, J.-M. Identification and evolution of drug efflux pump in clinical Enterobacter aerogenes strains isolated in 1995 and 2003. PLoS ONE, 2008, 3, e3203.
19. Sennhauser, G.; Bukowska, M. A.; Briand, C.; Grütter, M. G. Crystal structure of the multidrug exporter MexB from Pseudomonas aeruginosa. J. Mol Biol., 2009, 389, 134-145.
20. Pos, K. M. Drug transport mechanism of the AcrB efflux pump. Biochim. Biophys. Acta, 2009, 1794, 782-793.
21. Nishino, K.; Nikaido, E.; Yamaguchi, A. Regulation and physiological function of multidrug efflux pumps in Escherichia coli and Salmonella. Biochim. Biophys. Acta, 2009, 1794, 834-843.
22. Symmons, M. F.; Bokma, E.; Koronakis, E.; Hughes, C.; Koronakis, V. The assembled structure of a complete tripartite bacterial multidrug efflux pump. Proc. Natl. Acad. Sci. USA, 2009, 106, 7173-7178.
23. Pagès, J.-M.; Amaral, L. Mechanisms of drug efflux and strategies to combat them: challenging the efflux pump of Gram-negative bacteria. Biochim. Biophys. Acta., 2009, 1794, 826-833.
24. Mesaros, N.; Nordmann, P.; Plésiat, P.; Roussel-Delvallez, M.; Van Eldere, J.; Glupczynski, Y.; Van Laethem, Y.; Jacobs, F.; Lebecque, P.; Malfroot, A.; Tulkens, P. M.; Van Bambeke, F. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin. Microbiol. Infect., 2007, 13, 560-578.
25. Tal, N.; Schuldiner, S. A coordinated network of transporters with overlapping specificities provides a robust survival strategy. Proc. Natl. Acad. Sci. USA, 2009, 106, 9051-9056.
26. Mahamoud, A.; Chevalier, J.; Alibert-Franco, S.; Kern, V. W.; Pagès, J.-M. Antibiotic efflux pumps in Gram-negative bacteria: the inhibitor response strategy. J. Antimicrob. Chemother, 2007, 59, 1223-1229.
27. Lee, A.; Mao, W.; Warren, M. S.; Mistry, A.; Hoshino, K.; Okumura, R.; Ishida, H.; Lomovskaya, O. Interplay between efflux pumps may provide either additive or multiplicative effects on drug resistance. J. Bacteriol., 2000, 182, 3142-3150.
28. Lomovskaya, O.; Bostian, K. A. Practical applications and feasibility of efflux pump inhibitors in the clinic--a vision for applied use. Biochem. Pharmacol., 2006, 71, 910-918.
29. Lynch, A. S. Efflux systems in bacterial pathogens: an opportunity for therapeutic intervention? An industry view. Biochem. Pharmacol., 2006, 71, 949-956.
30. Bryskier, A. Antimicrobial Agents: Antibacterials and Antifungals. ASM Press, 2005, SBN 1-55581-237-6; 1456.
31. Stavri, M.; Piddock, L. J.; Gibbons, S. Bacterial efflux pump inhibitors from natural sources. J. Antimicrob. Chemother., 2007, 59, 1247-1260.
32. Stermitz, F. R.; Lorenz, P.; Tawara, J. N.; Zenewicz, L. A.; Lewis, K. Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5'-methoxyhydnocarpin; a multidrug pump inhibitor. Proc. Natl. Acad. Sci. USA, 2000, 97, 1433-1437.
33. Marra, A. Can virulence factors be viable antibacterial targets? Expert Rev. Anti Infect. Ther., 2004, 2, 61-72.
34. Woodford, N.; Wareham, D. W. UK Antibacterial Antisense Study Group. Tackling antibiotic resistance: a dose of common antisense? J. Antimicrob. Chemother., 2009, 63, 225-229.
35. Jeon, B.; Zhang, Q. Sensitization of Campylobacter jejuni to fluoroquinolone and macrolide antibiotics by antisense inhibition of the CmeABC multidrug efflux transporter. J. Antimicrob. Chemother., 2009, 63, 946-948.
36. White, D. G; Maneewannakul, K.; von Hofe, E.; Zillman, M.; Eisenberg, W.; Field, A. K.; Levy, S. B. Inhibition of the multiple antibiotic resistance (mar) operon in Escherichia coli by antisense DNA analogs. Antimicrob. Agents Chemother., 1997, 41, 2699-2704.
37. Van Bambeke, F.; Pagès, J.-M.; Lee, V. J. Inhibitors of bacterial efflux pumps as adjuvants in antibiotic treatments and diagnostic tools for detection of resistance by efflux. Recent Patents Anti-Infect Drug Discov., 2006, 1, 157-175.
38. Kiho, T.; Nakayama, M.; Yasuda, K.; Miyakoshi, S.; Inukai, M.; Kogen, H. Structure-activity relationships of globomycin analogues as antibiotics. Bioorg. Med. Chem., 2004, 12, 337-361.
39. Tokuda, H.; Matsuyama, S. Sorting of lipoproteins to the outer membrane in E. Coli. Biochim. Biophys. Acta, 2004, 1693, 5-13.
40. Malléa, M.; Chevalier, J.; Eyraud, A.; Pagès, J.-M. Inhibitors of antibiotic efflux pump in resistant Enterobacter aerogenes strains. Biochem. Biophys. Res. Comm., 2002, 293, 1370-1373.
41. Khandekar, S. S.; Daines, R. A.; Lonsdale, J. T. Bacterial betaketoacyl-acyl carrier protein synthases as targets for antibacterial agents. Curr. Protein Pept. Sci., 2003, 4, 21-29.
42. Pappenberger, G.; Schulz-Gasch, T.; Kusznir, E.; Müller, F.; Hennig, M. Structure-assisted discovery of an aminothiazole derivative as a lead molecule for inhibition of bacterial fatty-acid synthesis. Acta Crystallogr. D Biol. Crystallogr, 2007, 63, 1208-1216.
43. Khandekar, S. S.; Daines, R. A.; Lonsdale, J. T. Bacterial betaketoacyl-acyl carrier protein synthases as targets for antibacterial agents. Curr. Protein Pept. Sci., 2003, 4, 21-29.
44. Schweizer, H. P. Intrinsic resistance to inhibitors of fatty acid biosynthesis in Pseudomonas aeruginosa is due to efflux: application of a novel technique for generation of unmarked chromosomal mutations for the study of efflux systems. Antimicrob. Agents Chemother., 1998, 42, 394-398.
45. Falagas M. E.; Grammatikos, A. P.; Michalopoulos, A. Potential of old-generation antibiotics to address current need for new antibiotics. Expert Rev. Anti Infect. Ther., 2008, 6, 593-600.
46. Yeaman, M. R.; Yount, N. Y. Mechanisms of antimicrobial peptide action and resistance. Pharmacol. Rev., 2003, 55, 27-55.
47. Kraus, D.; Peschel, A. Molecular mechanisms of bacterial resistance to antimicrobial peptides. Curr. Top. Microbiol. Immunol., 2006, 306, 231-250.
48. Masi, M.; Saint, N.; Molle, G.; Pagès, J.-M. The Enterobacter aerogenes outer membrane efflux proteins TolC and EefC have different channel properties. Biochim. Biophys. Acta, 2007, 1768, 2559-2567.
49. Schulz, R.; Kleinekathöfer, U. Transitions between closed and open conformations of TolC: the effects of ions in simulations. Biophys. J., 2009, 96, 3116-3125.
50. Andersen, C.; Koronakis, E.; Bokma, E.; Eswaran, J.; Humphreys, D.; Hughes, C.; Koronakis, V. Transition to the open state of the TolC periplasmic tunnel entrance. Proc. Natl. Acad. Sci. USA, 2002, 99, 11103-11108.
51. Andersen, C.; Hughes, C.; Koronakis, V. Electrophysiological behavior of the TolC channel-tunnel in planar lipid bilayers. J. Membr. Biol., 2002, 185, 83-92.
52. Pagès, J.-M.; Masi, M.; Barbe, J. Inhibitors of efflux pumps in Gram-negative bacteria. Trends Mol. Med., 2005, 11, 382-389.
53. Lomovskaya, O.; Zgurskaya, H. I.; Totrov, M.; Watkins, W. J. Waltzing transporters and 'the dance macabre' between humans and bacteria. Nat. Rev. Drug Discov., 2007, 6, 56-65.
54. Renau, T. E.; Leger, R.; Flamme, E. M.; Sangalang, J.; She, M. W.; Yen, R.; Gannon, C. L.; Griffith, D.; Chamberland, S.; Lomovskaya, O.; Hecker, S. J.; Lee, V. J.; Ohta Nakayama, K. Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin. J. Med. Chem., 1999, 42, 4928-4931.
55. Lomovskaya, O.; Warren, M. S.; Lee, A.; Galazzo, J.; Fronko, R.; Lee, M.; Blais, J.; Cho, D.; Chamberland, S.; Renau, T. E.; Leger, R.; Hecker, S. J.; Watkins, W.; Hoshino, K.; Ishida, H.; Lee, V. J. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob. Agents Chemother., 2001, 45, 105-116.
56. Renau, T. E.; Léger, R.; Yen, R.; She, M. W.; Flamme, E. M.; Sangalang, J.; Gannon, C. L.; Chamberland, S.; Lomovskaya, O.; Lee, V. J. Peptidomimetics of efflux pump inhibitors potentiate the activity of levofloxacin in Pseudomonas aeruginosa. Bioorg. Med. Chem. Lett., 2002, 12, 763-766.
57. Renau, T. E.; Léger, R.; Filonova, L.; Flamme, E. M.; Wang, M.; Yen, R.; Madsen, D.; Griffith, D.; Chamberland, S.; Dudley, M. N.; Lee, V. J.; Lomovskaya, O.; Watkins, V. J.; Ohta, T.; Nakayama, K.; Ishida, Y. Conformationally-restricted analogues of efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginos.; Bioorg. Med. Chem. Lett., 2003, 13, 2755-2758.
58. Watkins, W. J.; Landaverry, Y.; Léger, R.; Litman, R.; Renau, T. E.; Williams, N.; Yen, R.; Zhang, J. Z.; Chamberland, S.; Madsen, D.; Griffith, D.; Tembe, V.; Huie K.; Dudley, M. N. The relationship between physicochemical properties; in vitro activity and pharmacokinetic profiles of analogues of diamine-containing efflux pump inhibitors. Bioorg. Med. Chem. Lett., 2003, 13, 4241-4244.
59. Murakami, S.; Nakashima, R.; Yamashita, E.; Matsumoto, T.; Yamaguchi, A. Crystal structures of a multidrug transporter reveal a functionally rotating mechanism. Nature, 2006, 443, 156-157.
60. Yu, E. W.; Aires, J. R.; McDermott, G.; Nikaido, H. A perisplasmic drug-binding site of the AcrB multidrug efflux pump: a crystallographic and site-directed mutagenesis study. J. Bacteriol., 2005, 187, 6804-6815.
61. Renau T. E.; Léger, R.; Flamme, E. M.; She, M. W.; Gannon, C. L.; Mathias, K. M.; Lomovskaya, O.; Chamberland, S.; Lee, V. J.; Ohta, T.; Nakayama, K.; Ishida, Y. Addressing the stability of Ccapped dipeptide efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa. Bioorg. Med. Chem. Lett., 2001, 11, 663-667.
62. Kriengkauykiat, J.; Porter, E.; Lomovskaya, O.; Wong-Beringer, A. Use of an efflux pump inhibitor to determine the prevalence of efflux pump-mediated fluoroquinolone resistance and multidrug resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother., 2005, 49, 565-570.
63. Nakayama, K.; Ishida, Y.; Ohtsuka, M.; Kawato, H.; Yoshida, K.; Yokomizo, Y.; Hosono, S.; Ohta, T.; Hoshino, K.; Ishida, H.; Yoshida, K.; Renau, T. E.; Léger, R.; Zhang, J. Z.; Lee, V. J.; Watkins, W. J. MexAB-OprM-specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 1: discovery and early strategies for lead optimization. Bioorg. Med. Chem. Lett., 2003, 13, 4201-4204.
64. Nakayama, K.; Ishida, Y.; Ohtsuka, M.; Kawato, H.; Yoshida, K.; Yokomizo, Y.; Ohta, T.; Hoshino, K.; Otani, T.; Kurosaka, Y.; Yoshida, K.; Ishida, H.; Lee, V. J.; Renau, T. E.; Watkins, W. J. MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 2: achieving activity in vivo through the use of alternative scaffolds. Bioorg. Med. Chem. Lett., 2003, 13, 4205-4208.
65. Nakayama, K.; Kawato, H.; Watanabe, J.; Ohtsuka, M.; Yoshida, K.; Yokomizo, Y.; Sakamoto, A.; Kuru, N.; Ohta, T.; Hoshino, K.; Yoshida, K.; Ishida, H.; Cho, A.; Palme, M. H.; Zhang, Z. J.; Lee, V. J.; Watkins, W. J. MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 3: Optimization of potency in the pyridopyrimidine series through the application of a pharmacophore model. Bioorg. Med. Chem. Lett., 2004, 14, 475-479.
66. Nakayama, K.; Kuru, N.; Ohtsuka, M.; Yokomizo, Y.; Sakamoto, A.; Kawato, H.; Yoshida, K.; Ohta, T.; Hoshino, K.; Akimoto, K.; Itoh, J.; Ishida, H.; Cho, A.; Palme, M. H.; Zhang, J. Z.; Lee, V. J.; Watkins, W. J. MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 4: Addressing the problem of poor stability due to photoisomerization of an acrylic acid moiety. Bioorg. Med. Chem. Lett., 2004, 14, 2493-2497.
67. Yoshida, K.; Nakayama, K.; Kuru, N.; Kobayashi, S.; Ohtsuka, M.; Takemura, M.; Hoshino, K.; Kanda, H.; Zhang, J. Z.; Lee, V. J., Watkins, W. J. MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa; Part 5: Carbon-substituted analogues at the C-2 position. Bioorg. Med. Chem., 2006, 14, 1993-2004.
68. Yoshida, K.; Nakayama, K.; Yokomizo, Y.; Ohtsuka, M.; Takemura, M.; Hoshino, K.; Kanda, H.; Namba, K.; Nitanai, H.; Zhang, J. Z.; Lee, V. J.; Watkins, W. J. MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa; Part 6: exploration of aromatic substituents. Bioorg. Med. Chem., 2006, 14, 8506-8518.
69. Yoshida, K.; Nakayama, K.; Ohtsuka, M.; Kuru, N.; Yokomizo, Y.; Sakamoto, A.; Takemura, M.; Hoshino, K.; Kanda, H.; Nitanai, H.; Namba, K.; Yoshida, K.; Imamura, Y.; Zhang, J. Z.; Lee, V. J.; Watkins, W. J. MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa; Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001; a potential preclinical candidate. Bioorg. Med. Chem., 2007, 15, 7087-7097.
70. Chevalier, J.; Atifi, S.; Eyraud, A.; Mahamoud, A.; Barbe, J.; Pagès, J.-M. New pyridoquinoline derivatives as potential inhi-bitors of the fluoroquinolone efflux pump in resistant Enterobacter aerogenes strains. J. Med. Chem., 2001, 44, 4023-4026.
71. Gallo, S.; Chevalier, J.; Mahamoud, A.; Eyraud, A.; Pagès, J.-M.; Barbe, J. 4-Alkoxy and 4-thioalkoxyquinoline derivatives as chemosensitizers for the chloramphenicol resistant clinical Enterobacter aerogenes 27 strain. Int. J. Antimicrob. Agents, 2003, 22, 270-273.
72. Malléa, A.; Mahamoud, A.; Chevalier, J.; Alibert-Franco, S.; Brouant, P.; Barbe, J.; Pagès, J.-M. Alkylaminoquinolines inhibit bacterial antibiotic efflux pump in multidrug resistant clinical isolates. Biochemical. J., 2003, 376, 801-805.
73. Chevalier, J.; Bredin, J.; Mahamoud, A.; Malléa, M.; Barbe, J.; Pagès, J.-M. Inhibitors of antibiotic efflux pump in resistant Enterobacter aerogenes and Klebsiella pneumoniae strains. Antimicrob. Agents Chemother., 2004, 48, 1043-1046.
74. Ghisalberti, D.; Mahamoud, A.; Chevaqlier, J.; Baitiche, M.; Martino, M.; Pagès, J.-M.; Barbe, J. Chloroquinolines block antibiotic efflux pump in resistant Enterobacter aerogenes isolates. Int. J. Antimicrob. Agents, 2006, 27, 565-569.
75. Mahamoud, A.; Chevalier, J.; Davin-Regli, A.; Barbe, J.; Pagès, J.-M. Quinoline derivatives as promising inhibitors of antibiotic efflux pump in multidrug resistant Enterobacter aerogenes isolates. Curr. Drug Targets, 2006, 7, 843-847.
76. Seeger, M. A.; Schiefner, A.; Eicher, T.; Verrey, F.; Diederichs, K.; Pos, K. M. Structural asymmetry of AcrB trimer suggests a peristaltic pump mechanism. Science, 2006, 313, 1295-1298.
77. Thorarensen, A.; Presley-Bodnar, A. L.; Marotti, K. R.; Boyle, T. P.; Heckaman, C. L.; Bohanon, M. J.; Tomich, P. K.; Zurenko, G. E.; Sweeney, M. T.; Yagi, B. H. 3-Arylpiperidines as potentiators of existing antibacterial agents. Bioorg. Med. Chem. Lett., 2001, 11, 1903-1906.
78. Kaatz, G. W.; Moudgal, V. V.; Seo, S. M.; Hansen, J. B.; Kristiansen, J. E. Phenylpiperidine selective serotonin reuptake inhibitors interfere with multidrug efflux pump activity in Staphylococcus aureus. Int. J. Antimicrob. Agents, 2003, 22, 254-261.
79. Bohnert, J. A.; Kern, W. V. Selected arylpiperazines are capable of reversing multidrug resistance in Echerichia coli overexpressing RND efflux pumps. Antimicrob. Agents Chemother., 2005, 49, 849-852.
80. Schumacher, A.; Steinke, P.; Bohnert, J. A.; Akova, M.; Jonas, D.; Kern, W. V. Effect of 1-(1-naphthylmethyl)-piperazine; a novel putative efflux pump inhibitor; on antimicrobial drug susceptibility in clinical isolates of Enterobacteriaceae other than Escherichia coli. J. Antimicrob. Chemother., 2006, 57, 344-348.
81. Kern, W. V.; Steinke, P.; Schumacher, A.; Schuster, S.; von Baum, H.; Bohnert, J. A. Effect of 1-(1-naphthylmethyl)-piperazine; a novel putative efflux pump inhibitor; on antimicrobial drug susceptibility in clinical isolates of Escherichia coli. J. Antimicrob. Chemother., 2006, 57, 339-343.
82. Pannek, S.; Higgins, P. G.; Steinke, P.; Jonas, D.; Akova, M.; Bohnert, J. A.; Seifert, H.; Kern, W. V. Multidrug efflux inhibition in Acinetobacter baumannii: comparison between 1-(1-naphthylmethyl)- piperazine and phenyl-arginine-beta-naphthylamide. J. Antimicrob. Chemother., 2006, 57, 970-974.
83. Martins, M.; Dastidar, S. G.; Fanning, S.; Kristiansen, J. E.; Molnar, J.; Pagès, J.-M.; Schelz, Z.; Spengler, G.; Viveiros, M.; Amaral, L. Potential role of non-antibiotics (helper compounds) in the treatment of multidrug-resistant Gram-negative infections: mechanisms for their direct and indirect activities. Int. J. Antimicrob. Agents, 2008, 31, 198-208.
84. Chan, Y. Y.; Ong, Y. M.; Chua, K. L. Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. Antimicrob. Agents Chemother., 2007, 51, 623-630.
85. Bailey, A. M.; Paulsen, I. T.; Piddock, L. J. RamA confers multidrug resistance in Salmonella enterica via increased expression of acrB; which is inhibited by chlorpromazine. Antimicrob Agents Chemother., 2008, 52, 3604-3611.
86. Rodrigues, L.; Wagner, D.; Viveiros, M.; Sampaio, D.; Couto, I.; Vavra, M.; Kern, W. V.; Amaral, L. Thioridazine and chlorpromazine inhibition of ethidium bromide efflux in Mycobacterium avium and Mycobacterium smegmatis. J. Antimicrob. Chemother., 2008, 61, 1076-1082.
87. Amaral, L.; Martins, M.; Viveiros, M.; Molnar, J.; Kristiansen, J. E. Promising therapy of XDR-TB/MDR-TB with thioridazine an inhibitor of bacterial efflux pumps. Curr. Drug Targets, 2008, 9, 816-819.
88. Viveiros, M.; Martins, A.; Paixão, L.; Rodrigues, L.; Martins, M.; Couto, I.; Fähnrich, E.; Kern, W. V.; Amaral, L. Demonstration of intrinsic efflux activity of Escherichia coli K-12 AG100 by an automated ethidium bromide method. Int. J. Antimicrob. Agents, 2008, 31, 458-462.
89. Viveiros, M.; Martins, M.; Couto, I.; Rodrigues, I.; Spengler, G.; Martins, A.; Kristiansen, J. E.; Molnar, J.; Amaral, L. New methods for the identification of efflux mediated MDR bacteria; genetic assessment of regulators and efflux pump constituents; characterization of efflux systems and screening for inhibitors of efflux pumps. Curr. Drug Targets, 2008, 9, 760-778.
90. Nelson, M. L.; Park, B. H.; Andrews, J. S.; Georgian, V. A.; Thomas, R. C.; Levy, S. B. Inhibition of the tetracycline efflux antiport protein by 13-thio-substituted 5-hydroxy-6- deoxytetracyclines. J. Med. Chem., 1993, 36, 370-377.
91. Nelson, M. L.; Park, B. H.; Levy, S. B. Molecular requirements for the inhibition of the tetracycline antiport protein and the effect of potent inhibitors on the growth of tetracycline-resistant bacteria. J. Med. Chem., 1994, 37, 1355-1361.
92. Nelson, M. L.; Levy, S. B. Reversal of tetracycline resistance mediated by different bacterial tetracycline resistance determinants by an inhibitor of the Tet(B) antiport protein. Antimicrob. Agents Chemother., 1999, 43, 1719-1724.
93. Molnar, J.; Hever, A.; Fakla, I.; Fischer, J.; Ocsovski, I.; Aszalós, A. Inhibition of the transport function of membrane proteins by some substituted phenothiazines in E. coli and multidrug resistant tumor cells. Anticancer Res., 1997, 17, 481-486.
94. Amaral, L.; Viveiros, M.; Molnar, J. Antimicrobial activity of phenothiazines. In Vivo, 2004, 18, 725-731.
95. Amaral, L.; Martins, M.; Viveiros, M. Enhanced killing of intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps. J. Antimicrob. Chemother., 2007, 59, 1237-1246.
96. Martins, A.; Spengler, G.; Rodrigues, L.; Viveiros, M.; Ramos, J.; Martins, M.; Couto, I.; Fanning, S.; Pagès, J.-M.; Bolla, J. M.; Molnar, J.; Amaral, L. pH Modulation of efflux pump activity of multi-drug resistant Escherichia coli: protection during its passage and eventual colonization of the colon. PLoS One, 2009, 4(8), e6656.
97. Gibbons, S. Phytochemicals for bacterial resistance--strengths; weaknesses and opportunities. Planta Med., 2008, 74, 594-602.
98. Lewis, K.; Ausubel, F. M. Prospects for plant-derived antibacterials. Nat. Biotechnol., 2006, 24, 1504-1507.
99. Coutinho; H. D. M.; Costa J. G. M.; Lima; E. O.; Falcão-Silva; V. S.; Siqueira-Júnior J. P. Enhancement of the Antibiotic Activity against a Multiresistant Escherichia coli by Mentha arvensis L. and Chlorpromazine. Chemotherapy, 2008, 54, 328-330.
100. Coutinho, H. D.; Costa, J. G.; Lima, E. O.; Falcao-Silva, V. S.; Siqueira-Junior, J. P. Increasing of the aminoglicosyde antibiotic activity Against a multidrug-resistant E. coli by turnera ulmifolia L. and chlorpromazine. Biol. Res. Nurs., 2009, 11, 332-335.
101. Shin, S. Anti-Salmonella activity of lemongrass oil alone and in combination with antibiotics. Nat. Prod. Sci., 2005, 11, 160-164.
102. Thota, N.; Koul, S.; Reddy, M. V.; Sangwan, P. L.; Khan, I. A.; Kumar, A.; Raja, A. F.; Andotra, S. S.; Qazi, G. N. Citral derived amides as potent bacterial NorA efflux pump inhibitors. Bioorg. Med. Chem., 2008, 16, 6535-6543.
103. Natarajan, P.; Katta, S.; Andrei, I.; Babu Rao Ambati, V.; Leonida, M.; Haas, G. J. Positive antibacterial co-action between hop (Humulus lupulus) constituents and selected antibiotics. Phytomedicine, 2008 15, 194-201.
104. Gill A.O., Holley, R.A. Disruption of Escherichia coli; Listeria monocytogenes and Lactobacillus sakei cellular membranes by plant oil aromatics. Int. J. Food. Microbiol., 2006, 108, 1-9.
105. Hemaiswarya, S.; Doble, M. Synergistic interaction of eugenol with antibiotics against Gram negative bacteria. Phytomedicine, 2009, 16, 997-1005.
106. Lorenzi, V.; Muselli, A.; Bernardini, A. F.; Berti, L.; Pagès, J.-M.; Amaral, L.; Bolla, J. M. Geraniol restores antibiotic activities against multidrug-resistant isolates from gram-negative species. Antimicrob. Agents Chemother., 2009, 53, 2209-2211.
107. Seeger, M. A.; Von Ballmoos, C.; Eicher, T.; Brandstatter, L.; Verrey, F.; Diederichs, K.; Pos, K. M. Engineered disulfide bonds support the functional rotation mechanism of multidrug efflux pump AcrB. Nat. Struct. Mol. Biol., 2008, 15, 199-205.
108. Sennhauser, G.; Amstutz, P.; Briand, C.; Storchenegger, O.; Grütter, M. G. Drug export pathway of multidrug exporter AcrB revealed by DARPin inhibitors. PLoS Biol., 2007, 5, e7.
109. Murakami, S. Multidrug efflux transporter; AcrB-the pumping mechanism. Curr. Opin. Struct. Biol., 2008, 18, 459-465.
110. Seeger, M. A.; Diederichs, K.; Eicher, T.; Brandstätter, L.; Schiefner, A.; Verrey, F.; Pos, K. M. The AcrB efflux pump: conformational cycling and peristalsis lead to multidrug resistance. Curr. Drug Targets, 2008, 9, 729-749.
111. German, N.; Wei, P.; Kaatz, G. W.; Kerns, R. J. Synthesis and evaluation of fluoroquinolone derivatives as substrate-based inhibitors of bacterial efflux pumps. Eur. J. Med. Chem., 2008, 43(11), 2453-2463
112. Ball, A. R.; Casadei, G.; Samosorn, S.; Bremner, J. B.; Ausubel, F. M.; Moy, T. I.; Lewis, K. Conjugating berberine to a multidrug resistance pump inhibitor creates an effective antimicrobial. ACS Chem. Biol., 2006, 1, 594-600.